BioLineRx (), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the

NASDAQ Capital Market The Nasdaq Stock Market () (National Association of Securities Dealers Automated Quotations Stock Market) is an American stock exchange based in New York City. It is the most active stock trading venue in the US by volume, and ranked second ...

and on the

Tel Aviv Stock Exchange The Tel Aviv Stock Exchange (TASE; ; colloquially known as The Bursa, ) is Israel's only public stock exchange and a public company that has been traded on the Tel-Aviv Stock Exchange since August 1, 2019. Legally, the exchange is regulated by ...

Corporate history

The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the

Jerusalem Development Authority The Jerusalem Development Authority (), or JDA, is a joint agency of the Israeli government and the Jerusalem Municipality that works to promote and develop the economy of the city of Jerusalem. The Authority was founded by Uziel Wexler and was es ...

, Yehuda Zisapel, and other investors. It executed an

initial public offering An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors and usually also to retail (individual) investors. An IPO is typically underwritten by one or more investment ...

on the Tel Aviv Stock Exchange in February 2007, raising 211 million

NIS Nis, Niš, NiS or NIS may refer to: Places * Niš, a city in Serbia * Nis, Iran, a village * Ness, Lewis ( gd, Nis, links=no), a village in the Outer Hebrides islands Businesses and organizations * Naftna Industrija Srbije, Petroleum Industry o ...

($50 million) – the TASE's largest biotech IPO until that time. In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market. In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for

Hepatitis C Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver; it is a type of viral hepatitis. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, a ...

. At the end of 2014,

Novartis Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, Massachusetts, United States (global research).name="novartis.com">https://www.novartis.com/research-development/research-loc ...

acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.

Management

Morris Laster, (M.D.) an alumnus of.

Downstate Medical Center SUNY Downstate Health Sciences University (Downstate) is a public medical school and hospital in Brooklyn, New York. It is the southernmost member of the State University of New York (SUNY) system and the only academic medical center for healt ...

, was

CEO A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especially ...

of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of

Tel Aviv University Tel Aviv University (TAU) ( he, אוּנִיבֶרְסִיטַת תֵּל אָבִיב, ''Universitat Tel Aviv'') is a public research university in Tel Aviv, Israel. With over 30,000 students, it is the largest university in the country. Locate ...

early in 2010. Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.

Operations

BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs. The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound. In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.

Pipeline

Below is a partial list of drug compounds in various stages of

development Development or developing may refer to: Arts *Development hell, when a project is stuck in development *Filmmaking, development phase, including finance and budgeting *Development (music), the process thematic material is reshaped * Photograph ...

by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited. * BL-1010 – orally available

neuropathic pain Neuropathic pain is pain caused by damage or disease affecting the somatosensory system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous ...

* BL-1020 – orally available GABA-enhanced antipsychotic for treatment of

schizophrenia Schizophrenia is a mental disorder characterized by continuous or relapsing episodes of psychosis. Major symptoms include hallucinations (typically hearing voices), delusions, and disorganized thinking. Other symptoms include social withdra ...

* BL-1021 – orally available

small molecule Within the fields of molecular biology and pharmacology, a small molecule or micromolecule is a low molecular weight (≤ 1000 daltons) organic compound that may regulate a biological process, with a size on the order of 1 nm. Many drugs ar ...

for treatment of

* BL-1040 – liquid polymer injected into patients with

acute myocardial infarction A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops to the coronary artery of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may tr ...

, invented by Smadar Cohen of

Ben-Gurion University Ben-Gurion University of the Negev (BGU) ( he, אוניברסיטת בן-גוריון בנגב, ''Universitat Ben-Guriyon baNegev'') is a public research university in Beersheba, Israel. Ben-Gurion University of the Negev has five campuses: the ...

* BL-1230 - a selective cannabinoid receptor type 2 ( CB2R) agonist for Dry Eye Syndrome (DES) * BL-5010 – cream treatment for

seborrheic keratosis A seborrheic keratosis is a non-cancerous (benign) skin tumour that originates from cells, namely keratinocytes, in the outer layer of the skin called the epidermis. Like liver spots, seborrheic keratoses are seen more often as people age. The tum ...

skin lesions * BL-7040 – orally available

anti-inflammatory drug Anti-inflammatory is the property of a substance or treatment that reduces inflammation or swelling. Anti-inflammatory drugs, also called anti-inflammatories, make up about half of analgesics. These drugs remedy pain by reducing inflammation as o ...

invented by Hermona Soreq of the

Hebrew University of Jerusalem The Hebrew University of Jerusalem (HUJI; he, הַאוּנִיבֶרְסִיטָה הַעִבְרִית בִּירוּשָׁלַיִם) is a public research university based in Jerusalem, Israel. Co-founded by Albert Einstein and Dr. Chaim Weiz ...

* BL-8020 – orally administered treatment for Hepatitis C, developed by Philippe Halfon, co-founder and President of Genoscience. * BL-8030 – second-generation NS3

protease A protease (also called a peptidase, proteinase, or proteolytic enzyme) is an enzyme that catalyzes (increases reaction rate or "speeds up") proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the ...

inhibitor for oral treatment of Hepatitis C, invented by Philippe Halfon

References

External links